Nodality Inc.

Single cell network profiling (SCNP) using multiparameter flow cytometry can measure compound effects on multiple signaling cascades in a cell-type-specific manner. We applied SCNP to a panel of compounds with reported inhibitory effects on Jak/Stat signaling using a novel system where modulation of multiple signaling cascades are simultaneously measured in discrete cell subsets in whole (ie, unfractionated) blood.

Main

Foundation

12/01/2003

The company is found by Garry Nolan and Omar Perez. Nodality’s proprietary technology is based on research first performed by Gary Nolan at Stanford University. Nodality licenses the technology from Stanford. Nodality has taken the original research and developed an advanced solution that characterizes individual cancer cells using advanced flow cytometry.

Publications

Cell Article

2004

Single cell profiling of potentiated phospho-protein networks in cancer cells.
Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, and Nolan GP.

Nature Rev Cancer article

2006

Mapping normal and cancer cell signalling networks: towards single-cell proteomics.
Irish JM, Kotech N, and Nolan GP.
Nature Rev Cancer. 2006;6:146-55.

Nat Methods Article

2006

Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.
Krutzik PO and Nolan GP.

Nat Chem Biol Article

2007

What's wrong with drug screening today.
Nolan GP.
Nat Chem Biol. 2007;3:187-191.

Response to ara-C based induction therapy in patients with AML

2008

Distinct proteomic signaling networks stratify response to ara-C based induction therapy in patients with acute myeloid leukemia (AML).
Minden M, Rosen D, Putta S, Cohen A, Francis-Lang H, Covey T, Woronicz J, Soper D, Long B, Cordeiro J, Panganiban-Lustan L, Banville S, Gayko U, Cesano A, and Fantl W.
Poster presented at: 50th Annual Meeting of the American Society of Hematology; December 6–9, 2008; San Francisco, CA.

SCNP to identify AML chemotherapy resistant cell phenotypes in vivo

2009

Single cell network profiling as a tool to identify AML chemotherapy resistant cell phenotypes under in vivo therapeutic pressure.
Cesano A, Woronicz J, Cohen AC, Covey T, Putta S, Gayko U, Fantl WJ, and Kornblau SM.
Paper presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.

Informatics platform and workflows

2010

Informatics platform and workflows for robust high throughput single cell network profiling (SCNP).
Putta S, Spellmeyer D, Evensen E, Banville S, Friedland B, Rosen D, Soper D, Purvis N, Covey T, Francis-Lang H, and McCarthy J.
Paper presented at: 25th Congress of the International Society for the Advancement of Cytometry; May 8–12, 2010; Seattle, WA.

PLoS One Article

10/27/2010

Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP)

SCNP in age- and disease-based heterogeneity

12/12/2011

Single cell network profiling (SCNP) reveals age- and disease-based heterogeneity in healthy individuals and in patients with low risk (LR) myelodysplastic syndrome (MDS).
Cohen AC, Huang Y-W, Cesano A, Hawtin RE, Ware JR, Arulrajah B, and Kornblau SM.
Poster presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.

Validation study results in pediatric patients with de novo AML

12/12/2011

Single cell network profiling (SCNP)-based classifier to predict response to induction therapy in pediatric patients with de novo acute myeloid leukemia (AML): validation study results.
Lacayo NJ, Alonzo TA, Gayko U, Westfall M, Purvis N, Putta S, Hackett J, Cohen AC, Gerbing RB, Dahl GV, Bamis AS, and Meshinchi S.
Poster presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.

Development of biomarkers and companion diagnostics.

2012

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR, Johnson BE, and Sledge GW.
Clin Cancer Res 2012;18:619-624.

Results form SCNP in chronic lymphocytic leukemia

2012

Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan X, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zaanotti R, Rai KR, Chiorazzi N, Pizzolo G, and Scupoli MT.
Haematologica 2012;97. [ePub ahead of print]

SCNP-based classifier to predict response in elderly patients with AML

12/10/2012

Single cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderly patients with acute myeloid leukemia (AML): Validation in two independent sample sets from ECOG and SWOG trials.
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer D, Marimpietri C, Hackett J, Shi J, Paietta E, Tallman MS, Cripe LD, Atwater SK, Appelbaum FR, and Radich JP.
Poster presented at: 54th Annual Meeting of the American Society of Hematology; December 8–11 2012; Atlanta, GA.

SCNP in chronic lymphocytic leukemia

12/10/2012

Single cell network profiling (SCNP) identifies altered signaling between patient risk groups in B-cell chronic lymphocytic leukemia (B-CLL).
Ptacek J, Evensen E, Friedland G, Cordeiro J, Ware JR, Chu CC, Damle RN, Zhang L, Chiorazzi N, Cesano A, and Hawtin RE.
Poster presented at: 54th Annual Meeting of the American Society of Hematology; December 8–11 2012; Atlanta, GA.

PLOS One Article

2013

Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A, Putta S, Rosen DB, Cohen AC, Gayko U, Mathi K, Woronics J, Hawtin RE, Cripe L, Sun Z, Tallman MS, and Paietta E.
PLOS One 2013;8(2):e56714.

British Journal of Haematology Article

2013

Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, and Meshinchi S.
British Journal of Haematology 2013; 10.1111/bjh.12370: ePub ahead of print.

SCNP in Bladder Cancer, Cytometry Part Article

2013

Single Cell Network Profiling Assay in Bladder Cancer.
Covey TM, Vira MA, Westfall M, Gulrajani M, Cholankeril M, Okhunov Z, Levey H, Marimpietri C, Hawtin R, Fields SZ, and Cesano A.
Cytometry Part A 2013; 83(1).

104th Annual Meeting of the American Association for Cancer Research

04/6/2013

Functional characterization of KIT and FcεR1 receptor mutations in Mast Cell Leukemia using Single Cell Network Profiling (SCNP).
Westfall M, Spector M, Gulrajani M, Marimpietri C, Kritharis A, Fields SZ, Allen SL, and Hawtin R.
Poster presented at: 104th Annual Meeting of the American Association for Cancer Research; April 6–10, 2013; Washington, DC.

Patents

FLUORESCENT DYE BINDING PEPTIDES (G Nolan)

04/27/2000

WO/2000/023463, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Methods for screening ... (G Nolan)

10/10/2002

20020146710 - Methods for screening for transdominant intracellular effector peptides and RNA molecules

Activation state (Perez, Nolan)

08/14/2003

WO/2003/067210 - METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF THE MULTIPLE PROTEINS IN SINGLE CELLS
Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

SINGLE CELL ASSESSMENT OF VIRAL INFECTION/REPLICATION (Perez, Nolan)

08/28/2003

WO/2003/070973 - SINGLE CELL ASSESSMENT OF VIRAL INFECTION/REPLICATION
STANFORD UNIVERSITY

Detecting receptor-ligand interactions in single cells (Perez, Nolan)

08/23/2007

20070196869 - Methods and compositions for detecting receptor-ligand interactions in single cells
Omar Perez

METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL

11/05/2009

(WO2009134944) METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL
Iventors
FANTL, Wendy, J.;
FRANCIS-LANG, Helen, L.;
COHEN, Aileen, C.;
NOLAN, Garry, P.
Applicants
NODALITY, INC. (For All Designated States Except US).
FANTL, Wendy, J. (For US Only).
FRANCIS-LANG, Helen, L. (For US Only).
COHEN, Aileen, C. (For US Only).
NOLAN, Garry, P. (US) (For US Only)

Method for Monitoring Vaccine Response Using Single Cell Network Profiling

10/27/2011

8,214,157 Method and apparatus for representing multidimensional data

07/24/2012

Nodality receives three key us patents in oncology and autoimmune diseases.
8,227,202 Methods for diagnosis, prognosis and methods of treatment
8,187,885 Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
8,214,157 Method and apparatus for representing multidimensional data

Phil McGarrigle, Nodality's General Counsel and Chief IP Officer: “These new patents build on Nodality's growing intellectual property portfolio which includes over 35 internally generated patent families and nine in-licensed patents.”

8,227,202 Methods for diagnosis, prognosis and methods of treatment

07/24/2012

Nodality receives three key us patents in oncology and autoimmune diseases.
8,227,202 Methods for diagnosis, prognosis and methods of treatment
8,187,885 Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
8,214,157 Method and apparatus for representing multidimensional data

Phil McGarrigle, Nodality's General Counsel and Chief IP Officer: “These new patents build on Nodality's growing intellectual property portfolio which includes over 35 internally generated patent families and nine in-licensed patents.”

8,187,885 Microbead kit and method for quantitative calibration

07/24/2012

8,187,885 Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
Nodality receives three key us patents in oncology and autoimmune diseases.
8,227,202 Methods for diagnosis, prognosis and methods of treatment
8,187,885 Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
8,214,157 Method and apparatus for representing multidimensional data

Phil McGarrigle, Nodality's General Counsel and Chief IP Officer: “These new patents build on Nodality's growing intellectual property portfolio which includes over 35 internally generated patent families and nine in-licensed patents.”

BENCHMARKS FOR NORMAL CELL IDENTIFICATION

8/1/2013

Collaboration

Celgene Corporation

07/16/2010

Announced a collaboration with Celgene Corporation to support early stage clinical drug development.
Under the terms of the agreement, Celgene will fund research conducted by Nodality using Single Cell Network Profiling (SCNP) technology to facilitate more efficient therapeutics development.

UCB Pharma S.A.

02/10/2012

Nodality, Inc. and UCB Pharma S.A. (Euronext Brussels: UCB) today announced a strategic collaboration utilizing Nodality's proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds. The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders. Based on information generated using Nodality's technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB's compounds.
Ismail Kola, UCB said, “…This collaboration represents a key component of UCB's strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms ...”

Pfizer Inc.

08/09/2012

Nodality, Inc. announced a strategic collaboration with Pfizer Inc. for the use of Nodality's proprietary Single Cell Network Profiling (SCNP) technology as a tool for the development of Pfizer compounds. The agreement establishes a multi-year, collaborative effort that will initially focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. The agreement also provides Pfizer the option to engage Nodality in companion diagnostics development. The terms of the agreement include an upfront payment, R&D funding, and success-based milestone payments.

Johnson & Johnson Innovation Center under an agreement with Janssen Biotech

01/08/2014

Nodality, Inc. announced today a strategic collaboration facilitated by the Johnson & Johnson Innovation Center in California under an agreement with Janssen Biotech, Inc. (“Janssen”) to apply Nodality's proprietary Single Cell Network Profiling (SCNP) technology to immunology R&D programs. The goal of the collaboration is to improve the development and probability of success of compounds for the treatment of rheumatoid arthritis and inflammatory bowel disease by further understanding the biologic function and activity at the single cell level. The agreement also provides an option to develop companion diagnostics that may arise from the collaboration.
Under the terms of the agreement, Nodality will receive an upfront payment and support for research activities.

Fundraising

$11.1 million from Kleiner Perkins Caulfield & Byers and TPG Biotechnology.

02/01/2007

It has raised $11.1 million in Series A financing, with proceeds from Kleiner Perkins Caulfield & Byers and TPG Biotechnology.
Risa Stack, Ph.D., a partner in Kleiner Perkins Caulfield and Byers, and Fred Cohen, M.D., Ph.D., partner and managing director of TPG Biotechnology have joined the company's Board of Directors.

$20 million from Maverick Capital and Pfizer Venture Investments.

03/16/2009

Announced it has completed a $20 million Series B funding, from Maverick Capital and Pfizer Venture Investments.
David B. Singer, a limited partner at Maverick Capital has joined the company's Board of Directors.
Proceeds from this financing will be used to advance research activities associated with the company's first test in acute myeloid leukemia, as well as to advance ongoing and new research and development programs in other hematologic malignancies, autoimmune diseases, and solid tumors.

$15.5 million by Pfizer Ventures, KPC&Byers, TPG and Maverick

03/22/2010

Announced it completed financing in which the company raised $15.5 million. The round was led by Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), a previous investor in Nodality, and Laboratory Corporation of America Holdings (NYSE:LH), with additional participation from previous investors, including Kleiner Perkins Caulfield & Byers, TPG Biotechnology, and Maverick Capital. Proceeds from this financing will be used to support commercial activities associated with the company's launch of its first test in acute myelogenous leukemia, as well as to advance ongoing and new research and development programs in other hematologic malignancies, autoimmune diseases, and solid tumors.

$15 million

07/17/2012

Announced that it has raised an additional $15 million in financing. Current investors Kleiner Perkins Caulfield & Byers, TPG Biotechnology, Maverick Capital and Pfizer Ventures co-led the round.

Validation

Announcement of promising data related to the application of (SCNP)

11/29/2010

Announced presentation of promising data related to the application of the company's novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies.
“…SCNP provides new insights into the biology of hematological cancers which is relevant to disease prognosis and response/resistance to therapy, and it establishes Nodality's leading presence in AML, a disease that remains a large area of unmet need,” stated David R. Parkinson.

Clinical Lab CLIA certification

06/28/2012

Announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its clinical laboratory in South San Francisco, California. This certification follows achievement of a California State license in September 2011. CLIA applies to all clinical laboratories operating in the U.S. and its territories and encompasses more than 200,000 clinical testing sites.
Alessandra Cesano: “CLIA certification is a critical step in the growth of our company as we develop SCNP-based products and assays, and prepare toward future commercialization.”

Data Presentations At Aacr 2013 Annual Meeting

04/11/2013

Nodality, Inc. announces Data Presentations At Aacr 2013 Annual Meeting: Single Cell Network Profiling (SCNP) Technology Demonstrates Successful Applications in Blood and Lung Cancers.

Reports Promising Rheumatoid Arthritis Study Results

08/26/2013

Nodality, Inc. Reports Promising Rheumatoid Arthritis Study Results To Predict Patient Treatment Response To Tnf Inhibitors.
Announced today results of the Company's comprehensive research study to identify cell markers (biomarkers) of disease activity and treatment success in rheumatoid arthritis (RA) patients. The study findings demonstrated that Nodality's SCNP technology, which measures functional pathways at the single cell level, can be used to identify biomarkers of responsiveness to treatment with tumor necrosis factor inhibitors (TNFIs).

Announced promising data utilizing SCNP in metastatic melanoma

11/12/2013

Announced promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma.

Appointments

Partners from KPC and TPG have joined the Board of Directors

02/01/2007

Risa Stack, Ph.D., a partner in Kleiner Perkins Caulfield and Byers, and Fred Cohen, M.D., Ph.D., partner and managing director of TPG Biotechnology have joined the company's Board of Directors.

David R. Parkinson, M.D. as its first president and chief executive officer.

09/24/2007

Announced the appointment of David R. Parkinson, M.D., the former senior medical officer at Biogen Idec, as its first president and chief executive officer. Previously, he held several senior oncology positions at Novartis. He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently is a member of the FDA's Science Board.

David B. Singer from Maverick Capital has joined the Board of Directors.

03/16/2009

David B. Singer, a limited partner at Maverick Capital has joined the company's Board of Directors.
Proceeds from this financing will be used to advance research activities associated with the company's first test in acute myeloid leukemia, as well as to advance ongoing and new research and development programs in other hematologic malignancies, autoimmune diseases, and solid tumors.

Gregory Critchfield, M.D., M.S., has joined the company's Board of Directors

12/13/2010

Announced that Gregory Critchfield, M.D., M.S., has joined the company's Board of Directors (recently serving as President of Myriad Genetic Laboratories, Inc.)

Michael Goldberg as executive chairman of the board of directors

06/01/2011

Nodality, inc. appoints Michael Goldberg as executive chairman of the board of directors (company founder, CEO, board member and venture capitalist). Michael joined Nodality's board to help guide the commercialization of SCNP.

Daniel Dornbusch as vice president of business development

08/01/2011

Daniel Dornbusch as vice president of business development (previously Novartis, Genentech, and Genzyme).

Laura Brege As Ceo

09/24/2012

Nodality, Inc. Appoints Laura Brege As Ceo (previously Onyx Pharmaceuticals, Inc., Red Rock Capital Management, a venture capital firm)

Guy Cavet, ph.d., as chief information officer, head of computational sciences

03/04/2013

Nodality, inc. Expands senior team, appoints Guy Cavet, ph.d., as chief information officer, head of computational sciences.
(previously Kaggle, Inc., Vice President, Informatics at Crescendo Bioscience, where he built the company's informatics organization, Senior Scientist, Bioinformatics at Genentech).

Ralph Snyderman, M.D., To Board Of Directors.

02/26/2014

Nodality, Inc. appoints Ralph Snyderman, M.D., To Board Of Directors. (formerly worked for Health Affairs and Dean of Duke's School of Medicine, led the creation of the Duke Clinical Research Institute (DCRI), the largest academic clinical research institute in the world. Worked at Genentech, Inc.)

Events

“Most Promising Company” at the Personalized Medicine World Conference 2011

01/11/2011

Nodality Takes Top Honors as “Most Promising Company” at the Personalized Medicine World Conference 2011.

2013 American College Of Rheumatology Annual Meeting

10/28/2013

Nodality, Inc. announces Presentations At 2013 American College Of Rheumatology Annual Meeting.